Strides Pharma Science Second Quarter 2025 Earnings: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Simply Wall St

October 26, 2024

Strides Pharma Science (NSE:STAR) Second Quarter 2025 Results

Key Financial Results

Revenue: ₹12.0b (up 20% from 2Q 2024).
Net income: ₹932.3m (up from ₹1.31b loss in 2Q 2024).
Profit margin: 7.8% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue.
EPS: ₹10.14 (up from ₹14.54 loss in 2Q 2024).

earnings-and-revenue-growth — NSEI:STAR Earnings and Revenue Growth October 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Strides Pharma Science Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 7.4% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Strides Pharma Science that we have uncovered.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.